



NEWS RELEASE

Silence Therapeutics to Participate in Fireside Chat at the RBC Capital Markets Global Healthcare Conference

5/12/2021

Silence Therapeutics to Participate in Fireside Chat at the RBC Capital Markets Global Healthcare Conference

12 May 2021

LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced the Company will participate in a fireside chat at the virtual RBC Capital Markets Global Healthcare Conference on Wednesday, May 19th at 8:35 a.m. ET / 1:35 p.m. BST

A live webcast of the presentation can be accessed via the Investors section of Silence's website at www.silence-therapeutics.com. An archived replay of the webcast will be available on the Company's website following the conference.

Enquiries:

Silence Therapeutics plc
Gem Hopkins, Head of IR and Corporate Communications

Tel: +1 (646) 637-3208

ir@silence-therapeutics.com

Investec Bank plc(Nominated Adviser and Broker)

Tel: +44 (0) 20 7597 5970

Daniel Adams/Gary Clarence

European P R

Tel: +44 (0) 20 3709 5700

Consilium Strategic Communications

Mary-Jane Elliott/ Angela Gray / Chris Welsh

silencetherapeutics@consilium-comms.com

About Silence Therapeutics

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron loading anemias. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda, among others. For more information, please visit <https://www.silence-therapeutics.com/>.

Source: Silence Therapeutics plc